Sandoz (SDZNY)

Executive Summary

Sandoz, a global leader in generic pharmaceuticals and biosimilars, is executing a strategic transformation to drive growth and margin expansion. The company leverages its scale in off-patent medicines while accelerating its biosimilar pipeline, targeting high-value biologics. Key recent approvals include a biosimilar for Stelara (ustekinumab) and a generic version of Entresto, which are contributing to revenue diversification. Sandoz's focus on complex generics and biosimilars positions it to capture market share from upcoming patent expiries, such as Humira biosimilars already launched and future launches for Xolair and Prolia. However, pricing pressure in generics and regulatory risks in biosimilars create headwinds. The company is also investing in operational efficiency and supply chain resilience. With a strong portfolio of over 1,500 molecules and a commercial presence in 100+ countries, Sandoz is well-positioned to sustain mid-single-digit revenue growth and improve margins through mix shift towards higher-value products. The upcoming catalysts include key FDA/EMA decisions and product launches that could reinforce its leadership in affordable medicines.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on biosimilar to Xolair (omalizumab)85% success
• Q4 2026EU launch of biosimilar to Prolia (denosumab)90% success
• Q2 2026US patent settlement for generic version of a blockbuster drug (e.g., Januvia)70% success